Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4324-4328

  Wei, Shuang ^a,b   Daniel, Benjamin J ^a,c   Brumlik, Michael J ^a,c   Burow, Matthew E ^a   Zou, Weiping ^a,b   Khan, Imtiaz A ^d,e   Wadsworth, Scott ^f   Siekierka, John ^f   Curiel, Tyler J ^a,c  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^f R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 4 ETHYL 2 (4 METHOXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; IMIDAZOPYRIMIDINE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PYRIDINYLIMIDAZOLE; PYRIMETHAMINE; RWJ 64809; RWJ 68198; SULFADIAZINE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENCEPHALITOZOON CUNICULI; ENZYME INHIBITION; FEMALE; FIBROBLAST; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; MICROSPORUM; MOUSE; NONHUMAN; PARASITE; PARASITOSIS; PRIORITY JOURNAL; TOXOPLASMA GONDII;

ANIMALS; ANTIGENS, CD8; ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENCEPHALITOZOON CUNICULI; ENCEPHALITOZOONOSIS; ENZYME INHIBITORS; FEMALE; HUMANS; IMIDAZOLES; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, KNOCKOUT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; TIME FACTORS; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

EID: 36749061310     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00680-07     Document Type: Article

References (20)

1. Adachi, T., B. K. Choudhury, S. Stafford, S. Sur, and R. Alam. 2000. The differential role of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase in eosinophil functions. J. Immunol. 165:2198-2204.
2. Boehm, J. C., J. M. Smietana, M. E. Sorenson, R. S. Garigipati, T. F. Gallagher, P. L. Sheldrake, J. Bradbeer, A. M. Badger, J. T. Laydon, J. C. Lee, L. M. Hillegass, D. E. Griswold, J. J. Breton, M. C. Chabot-Fletcher, and J. L. Adams. 1996. 1-Substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J. Med. Chem. 39:3929-3937.
3. Brumlik, M. J., S. Wei, K. Finstad, J. Nesbit, L. E. Hyman, M. Lacey, M. E. Burow, and T. J. Curiel. 2004. Identification of a novel mitogen-activated protein kinase in Toxoplasma gondii. Int. J. Parasitol. 34:1245-1254.
4. Curiel, T. J., E. C. Krug, M. B. Purner, P. Poignard, and R. L. Berens. 1993. Cloned human CD4+ cytotoxic T lymphocytes specific for Toxoplasma gondii lyse tachyzoite-infected target cells. J. Immunol. 151:2024-2031.
5. Derouin, F. 2001. Anti-toxoplasmosis drugs. Curr. Opin. Investig. Drugs 2:1368-1374.
6. Doerig, C. 2004. Protein kinases as targets for anti-parasitic chemotherapy. Biochim. Biophys. Acta 1697:155-168.
7. Dong, C., R. J. Davis, and R. A. Flavell. 2002. MAP kinases in the immune response. Annu. Rev. Immunol. 20:55-72.
8. + CTLs are essential for protective immunity against Encephalitozoon cuniculi infection. J. Immunol. 162:6086-6091.
9. Kultz, D. 1998. Phylogenetic and functional classification of mitogen- and stress-activated protein kinases. J. Mol. Evol. 46:571-588.
10. Lacey, M. R., M. J. Brumlik, R. E. Yenni, M. E. Burow, and T. J. Curiel. 2007. Toxoplasma gondii expresses two mitogen-activated protein kinase genes that represent distinct protozoan subfamilies. J. Mol. Evol. 64:4-14.
11. Luft, B. J., and J. S. Remington. 1992. Toxoplasmic encephalitis in AIDS. Clin. Infect. Dis. 15:211-222.
12. Montoya, J. G., and O. Liesenfeld. 2004. Toxoplasmosis. Lancet 363:1965-1976.
13. Parasrampuria, D. A., P. de Boer, D. Desai-Krieger, A. T. Chow, and C. R. Jones. 2003. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-inhuman study. J. Clin. Pharmacol. 43:406-413.
14. Pfefferkorn, E. R., and L. C. Pfefferkorn. 1977. Specific labeling of intracellular Toxoplasma gondii with uracil. J. Protozool. 24:449-453.
15. Saeij, J. P., J. P. Boyle, and J. C. Boothroyd. 2005. Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host. Trends Parasitol. 21:476-481.
16. Su, C., D. Evans, R. H. Cole, J. C. Kissinger, J. W. Ajioka, and L. D. Sibley. 2003. Recent expansion of Toxoplasma through enhanced oral transmission. Science 299:414-416.
17. Wadsworth, S. A., D. E. Cavender, S. A. Beers, P. Lalan, P. H. Schafer, E. A. Malloy, W. Wu, B. Fahmy, G. C. Olini, J. E. Davis, J. L. Pellegrino-Gensey, M. P. Wachter, and J. J. Siekierka. 1999. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther. 291:680-687.
18. Wei, S., F. Marches, J. Borvak, W. Zou, J. Channon, M. White, J. Radke, M. F. Cesbron-Delauw, and T. J. Curiel. 2002. Toxoplasma gondii-infected human myeloid dendritic cells induce T-lymphocyte dysfunction and contact-dependent apoptosis. Infect. Immun. 70:1750-1760.
19. Wei, S., F. Marches, B. Daniel, S. Sonda, K. Heidenreich, and T. Curiel. 2002. Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication. Int. J. Parasitol. 32:969-977.
20. Wiese, M. 1998. A mitogen-activated protein (MAP) kinase homologue of Leishmania mexicana is essential for parasite survival in the infected host. EMBO J. 17:2619-2628.